Biogen to Acquire Convergence, Expand Pain Pipeline
The biotech sector continues to witness mergers and acquisitions. Earlier this week, Biogen Idec ( BIIB ) announced its intention to acquire U.K.-based Convergence Pharmaceuticals, a clinical stage biopharmaceutical company with a focus on developing treatments for neuropathic pain. The Lead Candidate – CNV1014802 Once the acquisition goes through, Biogen will gain access to Convergence’s lead candidate, CNV1014802, which is in phase II development […]